Autologous Cell Therapy for Ischemic Heart Failure

Exclusion Criteria

• •Not under stable optimal medical management
• •Cardiac surgery or percutaneous coronary intervention within 3 months
• •Occurrence of myocardial infarction (MI) within 6 months, in the case of first MI, or 3 months, in the case of any subsequent MI
• •Prior cell, gene, or transmyocardial laser revascularization therapy
• •Ventricular wall thickness in target region ≤ 5 mm
• •Moderate to severe aortic valve stenosis or mechanical valve replacement
• •Left ventricular aneurysm or thrombus
• •Left ventricular dysfunction associated with a reversible cause
• •Vascular disease preventing percutaneous vascular access
• •History of myopathic disease
• •History of neoplasia within 5 years, except for basal cell carcinoma
• •Receiving or planning to receive anti-cancer medications
• •Serum creatinine \> 3.0 mg/dl
• •Pregnant, planning to become pregnant, or breastfeeding a child in the next 18 months
• •Life expectancy of less than 1 year
• •Morbid obesity (defined as BMI \> 35)
• •History of bleeding diathesis or coagulopathy
• •Positive for HIV, Hepatitis B, or Hepatitis C
• •Known hypersensitivity or contraindication to study product or treatment procedure
• •Enrolled in another research project at the time of enrollment
• •Unable to provide informed consent
• •Unable or unwilling to commit to the follow-up clinical procedures